

Time Table
Day 1, Thursday, February 22

| | | | | | | |
|----|--|---------------------------------|------------------------|------------------------|--------------------------------|-----------------|
| 凡例 | PS = Presidential Session | SJS = SIOG/JSMO Joint Symposium | CP = Committee Program | ES = Evening Seminar | HoD = Highlight of the Day | L = ライブ配信 |
| | AJS = ASCO/JSMO Joint Symposium | JS = Joint Symposium | ME = Meet The Experts | O = Oral Session | PAP = Patient Advocate Program | On = オンデマンド配信 |
| | APJS = Asia-Pacific/JSMO Joint Symposium | PSY = Presidential Symposium | MEs = Medical Seminar | MO = Mini Oral Session | | 同時通訳 (英⇄日) |
| | EJS = ESMO/JSMO Joint Symposium | SY = Symposium | MOs = Morning Seminar | P = Poster Session | | English Session |

| | | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | | |
|--|---|---|------------------------------------|---|---|---|---|--|---|---|---|---|---|---|--|--|
| Nagoya International Conference Center | Room 1 Century Hall 2F Bldg.1 | | | Opening Remarks | PSY1 L O 9:00-10:20 Infrastructure development for utilization of Real World Data P.103 | PSY2 L O 10:30-11:30 Perioperative treatment that changes with immune checkpoint inhibitor P.103 | | MeS1 12:35-13:25 The Past, Present, and Future of Cancer Immunotherapy "Tracing the Journey from Opdivo Approval" P.69 | PS1 L O E 13:40-15:40 Lung cancer/ Thoracic Cancer P.104 | HoD1 L O 16:00-17:10 Highlight of the Day 1 P.105 | | | ES1 18:20-19:10 BRCA1/2 germline testing to guide optimal treatment strategy for patients with pancreatic P.92 | | | |
| | Room 2 Reception Hall 4F Bldg.1 | | | SY1 L O E 9:00-10:30 Telemedicine in the field of cancer P.106 | | | Treatment Strategies for HER2 positive and HER2 low Metastatic Recurrent Breast Cancer: Activity and adverse event management P.69 | MeS2 L O 12:35-13:25 DCT for patient access ~ issues and expectation in early phase clinical trials ~ P.70 | SY2 L O E 13:40-15:10 Current landscape of adjuvant therapy for HER2-negative EBC P.106 | PSY3 L O 15:30-17:00 Advances in surgical treatment that medical oncologists want to know P.107 | | Clinical trial x over 1,500 patients Real World data, thinking about the best treatment strategy for advanced EGFRmNSCLC P.92 | ES2 L O E 18:20-19:10 | | | |
| | Room 3 Conference Rooms 141+142 4F Bldg.1 | | | JS1 9:15-11:15 Consider who will provide support for patients' distress after cancer treatment P.108 | | | Diagnosis and treatment of cancer of unknown primary - The reason why it is necessary to communicate between pathologist and clinician- P.111 | MeS3 E 12:35-13:25 The latest topics on the treatment for HCC P.69 | SY3 L O E 13:40-15:10 Tumor agnostic drug discovery and development P.108 | JS2 L O E 15:20-17:20 The forefront of translational researches in Japan P.109 | | | ES3 L O E 18:20-19:10 Recent Advances in the Treatment of Triple-Negative Breast Cancer P.92 | | | |
| | Room 4 International Conference Room 3F Bldg.3 | | | JS3 9:15-11:15 Onco-cardiology Guideline as a Bridgehead toward the Next Stage P.111 | | | Genetic Testing for BRCA1/2 in ordinary clinical practice: HBOC management and standard approaches to breast cancer treatment. P.114 | MeS4 L 12:35-13:25 P.70 | EJS L O E 13:40-15:10 Economic Issues in Cancer Care P.112 | | PAGA Forum P.112 | | | ES4 L O E 18:20-19:10 Current status and challenges of Patient and Public Involvement in Europe and Japan P.93 | | |
| | Room 5 Conference Rooms 431+432 3F Bldg.4 | | | O1 9:00-10:30 Lung Cancer/ Thoracic Cancer 1 (Non-Small Cell Lung Cancer-Immunotherapy 1) P.114 | MO1 E 10:30-11:30 Lung Cancer/ Thoracic Cancer 1 (Non-Small Cell Lung Cancer-Immunotherapy 1) P.114 | | | MeS5 12:35-13:25 P.70 | SY4 L O 13:40-15:10 What is the "new normal" of multi-center cancer clinical trial group? P.115 | SY5 L O E 15:30-17:00 Multidisciplinary approach for hepatocellular carcinoma P.116 | | Prospects for Comprehensive Genomic Profiling test for Cancer and Recent advances in genomic analysis of GI cancers P.93 | ESS L 18:20-19:10 P.93 | | | |
| | Room 6 Conference Rooms 131+132 3F Bldg.1 | | | MO2 E 9:00-10:00 Genitourinary Cancer 1 (Novel Strategies for the treatment of Genitourinary Cancer) P.117 | CP1 L O 10:00-11:30 Practical guideline for febrile neutropenia (3rd Edition) ~ Outline of the Clinical Practice Guidelines for Tumor-Agnostic Treatments in Adult and Pediatric Patients with Advanced Solid Tumors toward Precision Medicine (3.1 Edition) P.118 | | | MeS6 12:35-13:25 DCT for patient access ~ issues and expectation in early phase clinical trials ~ P.70 | MO3 E 13:40-14:40 Hepatobiliary/ Pancreatic Cancer 1 (Pancreatic Cancer 1) P.119 | MO4 E 14:40-15:40 Rare Cancer 1 (Neuroendocrine neoplasm, Thyroid cancer) P.120 | CP2 L O 15:40-17:10 Social Media Working Group Symposium P.121 | | ES6 L 18:20-19:10 Current Issues and Future Prospects in Comprehensive Genomic Profiling Test P.94 | | | |
| | Room 7 Conference Rooms 133+134 3F Bldg.1 | | | O2 9:00-10:30 Hepatobiliary/ Pancreatic Cancer P.122 | MO5 E 10:30-11:30 Hepatobiliary/ Pancreatic Cancer 2 (Pancreatic Cancer 2) P.123 | | | MeS7 12:35-13:25 The Latest Strategies for Preventing CINV P.71 | MO6 E 13:40-14:30 Rare Cancer 2 (Melanoma) P.123 | | MO7 E 16:10-17:10 Artificial Intelligence (AI) P.124 | | ES7 L 18:20-19:10 The Two Sides of Immunotherapies: The Balance Between Efficacy & Safety P.94 | | | |
| | Room 8 Conference Room 234 3F Bldg.2 | | | SY6 L O 9:00-10:30 Training Program for Improving Cancer Survivorship: Present and Future P.125 | MO8 E 10:30-11:30 Palliative Care/Symptom Management 1 P.125 | | Latest Topics on chemotherapy for Colorectal Cancer in 2024 - Continuum of Care in Colorectal Cancer Treatment - P.71 | MeS8 12:35-13:25 P.71 | SY7 L O 13:40-15:10 Isn't that treatment overkill? P.126 | | SY8 L O 15:30-17:00 Psychooncology Update ~ Evidence & Practice ~ P.127 | | ES8 18:20-19:10 Overcoming Challenges in Driver Mutation-Positive Colorectal Cancer: Insights and Solutions P.94 | | | |
| | Room 9 Conference Rooms 232+233 3F Bldg.2 | | | MO9 E 9:00-10:00 Breast Cancer 1 (HER2-negative breast cancer) P.129 | O3 10:00-11:30 Gastrointestinal Cancer 1 (Gastric Cancer) P.129 | | | MeS9 12:35-13:25 Personalized treatment strategy in the era of immunotherapy - What about squamous cell lung cancer? ~ P.71 | O4 13:40-15:10 Genitourinary Cancer P.130 | MO10 E 15:10-16:10 Lung Cancer/ Thoracic Cancer 2 (Non-Small Cell Lung Cancer-Immunotherapy 2) P.131 | MO11 E 16:10-17:10 Lung Cancer/ Thoracic Cancer 3 (Non-Small Cell Lung Cancer-TKI) P.132 | | ES9 L 18:20-19:10 New Wave for Diagnosis and Treatment in Driver-positive NSCLC patients P.95 | | | |
| | Room 10 Conference Room 224 2F Bldg.2 | | | SY9 L O E 9:00-10:30 Future aspects of cell therapy P.133 | MO12 E 10:30-11:30 Hematologic Malignancies 1 (Leukemia) P.133 | | | MeS10 L O 12:35-13:25 Frontier in Precision Cancer Medicine: Focusing on Liquid Biopsy and Guardant360 CDx P.72 | JS4 L O 13:40-15:40 For well-being of the cancer patients suffering from bone metastases: To develop a new horizon (onco-orthopaedics) P.134 | SY10 L O 15:40-17:10 Clinical pharmacological approaches to appropriate drug therapy for unmet needs P.135 | | Considering FN Management in Cancer Chemotherapy - Key Points of Guideline Revision and Expectations for G-Lasta BodyPod P.95 | ES10 L 18:20-19:10 Drug Resistance Mechanisms in Lung Cancer P.95 | | | |
| | Room 11 Conference Room 221 2F Bldg.2 | | | MO13 E 9:00-10:00 Gastrointestinal Cancer 1 (Gastric Cancer, HER2, MSI, GEJC) P.137 | MO14 10:00-11:00 Multidisciplinary Team Program 1 (International session) P.138 | | | MeS11 12:35-13:25 Onco-Cardiology Update - Appropriate Treatment and Collaboration - P.72 | MO15 E 13:40-14:40 Gastrointestinal Cancer 2 (Gastric Cancer, Others) P.138 | MO16 E 14:55-15:55 Gastrointestinal Cancer 3 (Gastric Cancer, ICH+Chemotherapy) P.139 | MO17 E 16:10-17:10 Gastrointestinal Cancer 4 (Gastric Cancer, 2nd/late-line chemotherapy) P.140 | | ES11 L 18:20-19:10 Gastrointestinal Cancer 4 (Gastric Cancer, 2nd/late-line chemotherapy) P.95 | | | |
| | Room 12 Conference Rooms 222+223 2F Bldg.2 | | | O5 9:00-10:20 Clinical Trial Facilitation Program P.141 | O6 10:20-11:40 Head and Neck Cancer P.142 | | | MeS12 12:35-13:25 Treatment Strategies for Brain Metastases in Non-Small Cell Lung Cancer P.72 | MO18 E 13:40-14:40 Gynecologic Cancer 1 P.142 | MO19 E 15:15-16:15 Breast Cancer 2 (HER2-expressing breast cancer) P.143 | MO20 E 16:15-17:15 Hematologic Malignancies 2 (Lymphoma 1) P.144 | | ES12 L 18:20-19:10 The Dawn of Precision Medicine in BRAF Mutation-Positive Solid Tumors P.96 | | | |
| | Room 13 Exhibition Room 211 1F Bldg.2 | | | MO21 E 9:00-10:00 Translational Research/ Clinical Pharmacology 1 (Basic Research) P.145 | SY11 L O E 10:00-11:30 To overcome resistance to immune checkpoint inhibitors ~ Rethinking the Use of Immune Checkpoint Inhibitors ~ P.146 | | Treatment Strategies in EGFR Mutation-Positive NSCLC P.73 | MeS13 12:35-13:25 P.73 | O7 13:40-15:10 Translational Research/ Clinical Pharmacology P.146 | O8 E 15:30-17:00 Gastrointestinal Cancer 2 (Esophageal Cancer/ Colorectal Cancer) P.147 | | Supporting Cancer Patients' Appearance: Exploring the Optimal Approach to Chemotherapy-Induced Alopecia P.96 | ES13 18:20-19:10 P.96 | | | |
| | Meet the Experts① Conference Room 436 3F Bldg.4 | | | ME1 9:00-10:00 Advanced Care Planning: What's wrong? What should we do? P.149 | ME2 E 10:15-11:15 Current Insights of Chemotherapy in Colorectal Cancer P.149 | | | | ME3 E 13:40-14:40 How I Treat Multiple myeloma P.149 | | ME4 E 15:30-16:30 Patient Involvement Globally: How patients are becoming integral to healthcare decisions, policies and practices P.149 | | | | | |
| | Meet the Experts② Conference Room 437 3F Bldg.4 | | | ME5 9:00-10:00 Rare Cancer Update P.150 | ME6 E 10:15-11:15 Resistance mechanism of targeted therapy for NSCLC with driver mutation. Next step P.150 | | | | ME7 E 13:40-14:40 Immune Surveillance: Perspectives in antigen recognition and response P.150 | | ME8 15:30-16:30 Cancer survivorship care: how can we contribute to survivors who live beyond treatment? P.151 | | | | | |
| | PAP Room Exhibition Room 212 1F Bldg.2 | | PAP1 8:45-9:00 PAP Orientation① | L PAP1 L O 9:00-9:45 PAP Basic Lecture① | | | | PAP1 L 12:30-13:15 Treatment and work in the era of cancer genomic medicine | PAP1 L O 13:25-14:10 PAP Basic Lecture② | PAP1 L O 14:20-15:05 PAP Basic Lecture③ | PAP1 L O 15:15-16:00 PAP Basic Lecture④ | PAP1 L O 16:10-16:55 PAP Basic Lecture⑤ | PAP1 L O 17:05-17:50 PAP Special Lecture① | | | |
| | Poster Room ① Cafeteria Cascade B1F, Bldg.3 ② Shirotori Hall 1F, Bldg.4 ③ Conference Room 438 3F, Bldg.4 ④ Aisle 3F, Bldg.3 ⑤ Lounge 3F, Bldg.2 | | | 8:00-9:00 Putting Up Posters | 9:00-11:40 Poster Display | 11:40-12:25 Poster Session | 12:25-13:30 Poster Removal & Putting Up Posters | | 13:30-14:10 Poster Display | | 13:30-17:25 Poster Session | 17:25-18:10 Poster Removal | | | | |

Time Table
Day 2, Friday, February 23

| | | | | | | |
|----|--|---------------------------------|------------------------|------------------------|--------------------------------|-----------------|
| 凡例 | PS = Presidential Session | SJS = SIOG/JSMO Joint Symposium | CP = Committee Program | ES = Evening Seminar | HoD = Highlight of the Day | L = ライブ配信 |
| | AJS = ASCO/JSMO Joint Symposium | JS = Joint Symposium | ME = Meet The Experts | O = Oral Session | PAP = Patient Advocate Program | O = オンデマンド配信 |
| | APJS = Asia-Pacific/JSMO Joint Symposium | PSY = Presidential Symposium | MeS = Medical Seminar | MO = Mini Oral Session | | 同時通訳 (英⇄日) |
| | EJS = ESMO/JSMO Joint Symposium | SY = Symposium | MoS = Morning Seminar | P = Poster Session | | English Session |

| | | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
|--|---|-----------|---|---|--------------------|--|--|---|---|--|---|---|--|--|----------------|
| Nagoya International Conference Center | Room 1 Century Hall | 2F Bldg.1 | | PS2 Gastrointestinal Cancer, Hematologic Malignancies, Genitourinary Cancer, Translational Research/ Clinical Pharmacology P.193 | | LOE 8:40-11:20 | | MeS17 State of the art - treatment for HR positive advanced breast cancer P.74 | 総会・授与式・受賞講演 13:30-14:50 | PS3 new ADC P.194 | LOE 15:00-17:00 | | ES14 Treatment strategy for patients with HER2 mutation+NSCLC P.97 | | |
| | Room 2 Reception Hall | 4F Bldg.1 | MoS1 ES-SSC treatment - A pursuit: Long-term survival & lung condition - P.83 | PSY4 Fostering the Future of Clinical Oncology through Multidisciplinary Collaboration P.195 | LOE 8:20-9:50 | SY12 Treatment Strategy of Cure for Patients with Thoracic Cancer P.196 | | MeS15 Expanding treatment paradigms in front line ovarian cancer P.74 | | HoD2 Highlight of the Day 2 P.196 | | | ES15 Novel Treatments in HER-2 Driven Metastatic Breast Cancer P.97 | | |
| | Room 3 Conference Rooms 141+142 | 4F Bldg.1 | MoS2 Cutting Edge Treatments for Gynecologic Cancer P.83 | SY13 UC medical oncology update: Know the true value of IO! P.198 | LOE 8:20-9:50 | PSY5 What should Japan do about cancer care in a super-aging society? P.199 | | MeS16 The Journey and Future of Precision Medicine in Colorectal Cancer P.74 | | | SY14 Precision medicine for colorectal cancer P.199 | LOE 15:00-16:40 | | ES16 Unanswered questions in CML P.97 | |
| | Room 4 International Conference Room | 3F Bldg.3 | MoS3 The latest treatment strategies in HER2 Positive Breast Cancer P.83 | SY15 Secure the safety of anti-cancer drug administration - Device selection, Extravasation and Phlebitis P.201 | LOE 8:20-9:50 | SY16 Next Stage of PPI (Patient and Public Involvement) in Japan- Involvement at the stage of regulatory approval and social implementation P.202 | | MeS17 The future direction of the treatment sequence in Advanced Gastric Cancer P.74 | | | AJS Drugging the Undruggable Targets P.202 | LOE 15:00-16:30 | | ES17 Treatment landscape in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Present status and Future Directions P.97 | |
| | Room 5 Conference Rooms 431+432 | 3F Bldg.4 | MoS4 Pharmacotherapy in Esophageal Cancer - Optimal treatment strategy for long-term survival- P.84 | JS5 Cancer Genome Medicine-Harmony for patients P.204 | LOE 8:20-10:20 | MO22 Patient Advocacy 1 P.204 | | MeS18 How to Genome in Pancreatic and Biliary Tract Cancers P.75 | | | JS6 Cancer precision medicine and multi-gene panel testing P.205 | LOE 15:00-17:00 | | ES18 Is drug loss in Japan caused by the drug price system? P.98 | |
| | Room 6 Conference Rooms 131+132 | 3F Bldg.1 | MoS5 Novel therapeutic strategies with FLT3 inhibitors in AML P.84 | MO23 Palliative Care/ Symptom Management 2 P.207 | E 8:20-9:20 | MO24 Cross-sectional Program 1 (Immunotherapy/ Targeted therapy) P.208 | MO25 Cross-sectional Program 2 (New targeted therapy/ Radiation therapy) P.208 | | MeS19 Summary of the current treatment of AML P.75 | | O9 Rare Cancer P.209 | E 15:00-16:30 | | ES19 Current status of mCSPC treatment P.98 | |
| | Room 7 Conference Rooms 133+134 | 3F Bldg.1 | MoS6 Practical perspectives on matched targeted therapy for advanced gastric cancer P.84 | MO26 Hematologic Malignancies 3 (Lymphoma 2) P.211 | E 8:20-9:20 | MO27 Rare Cancer 3 (Central Nervous System Tumor) P.211 | MO28 Multidisciplinary Team Program 2 P.212 | Is lorlatinib a game changer in the first-line treatment for ALK-positive NSCLC? -What is the best treatment option for patients? | MeS20 12:25-13:15 P.75 | | O10 Patient Advocacy P.213 | 15:00-16:30 | | ES20 Biomarker-based treatment strategy for colorectal cancer P.98 | |
| | Room 8 Conference Room 234 | 3F Bldg.2 | MoS7 Supportive and Palliative Therapies to Accomplish Cancer Treatment P.84 | SY17 Let's understand clinical trial results more deeper: Discussion with statistical and economical experts P.214 | LOE 8:20-10:00 | | CP3 Is Oncology Not Popular? Discussing the reality of medical school education [JSMO University] P.214 | | MeS21 Advancements of Treatment in EGFR+ NSCLC P.76 | | SY18 Current status of head and neck cancer treatment aiming at personalized medicine and the future of new technology development P.215 | LOE 15:00-16:30 | | ES21 Clinical achievement and future perspectives in follicular lymphoma P.98 | |
| | Room 9 Conference Rooms 232+233 | 3F Bldg.2 | MoS8 Multidisciplinary treatment approach of colorectal cancer based on the latest evidence in 2024 P.85 | CP4 Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region P.216 | LOE 8:20-9:50 | APJS Education for Oncologists P.216 | | MeS22 Clinical implementation and perspective of CGP testing in gastric and colorectal cancer P.76 | | | CP5 JSMO2024 Smoking Cessation Session P.217 | LOE 15:00-16:35 | | ES22 Review for the growth potential of NGS multiplex gene assay P.99 | |
| | Room 10 Conference Room 224 | 2F Bldg.2 | MoS9 Comprehensive genomic profiling of BTC P.85 | SY19 Genomic medicine and novel therapeutic strategy in blood cancer P.218 | LOE 8:20-9:50 | SY20 Treatment development for rare cancers P.218 | | MeS23 Current treatment landscape of HR+HER2- advanced breast cancer P.76 | | | SY21 Challenge and Perspective of treatment in the field of gynecologic oncology P.219 | LOE 15:00-16:30 | | ES23 Current status and future perspective of Keytruda for the treatment of esophageal cancer P.99 | |
| | Room 11 Conference Room 221 | 2F Bldg.2 | MoS10 Treatment Sequencing Strategies in EGFR mutant NSCLC -Statistical & clinical viewpoint- P.85 | MO29 Breast Cancer 3 (QOL) P.220 | E 8:20-9:10 | Breast Cancer 4 (Basic/ Translational research) P.220 | MO31 Gastrointestinal Cancer 5 (Esophageal Cancer, Perioperative, Others) P.221 | | MeS24 Key updates of perioperative and advanced NSCLC treatment P.77 | | MO32 Translational Research/ Clinical Pharmacology 2 (Comprehensive Genomic Profiling) P.222 | E 15:00-16:00 | MO33 Hepatobiliary/ Pancreatic Cancer 3 (Pancreatic Cancer 3 (Gallbladder and Biliary Tract Cancer 1) P.233 | ES24 Challenges of SCLC treatment, immunotherapy and the management of adverse events P.99 | |
| | Room 12 Conference Rooms 222+223 | 2F Bldg.2 | MoS11 NET Update - current status and future perspective - P.86 | O11 Lung Cancer/ Thoracic Cancer 2 P.224 | E 8:20-9:50 | O12 Palliative Care/ Symptom Management P.225 | | MeS25 Implementation of Task Shift/ Sharing - A Model for Team Medicine in Cancer Cachexia - P.77 | | MO34 Lung Cancer/ Thoracic Cancer 4 (Non-Small Cell Lung Cancer-Chemotherapy・TKI) P.226 | E 15:00-16:00 | MO35 Lung Cancer/ Thoracic Cancer 5 (Non-Small Cell Lung Cancer-Locally Advanced・ Perioperative Treatment) P.226 | | ES25 Current Topics in Ovarian Cancer Treatment P.100 | |
| | Room 13 Exhibition Room 211 | 1F Bldg.2 | MoS12 ICI + Chemotherapy in elderly patients with Lung Cancer P.86 | O13 Gynecologic Cancer P.228 | E 8:20-9:50 | O14 Cross-sectional Program P.229 | | MeS26 Personalized Lung Cancer Treatment - Aiming for Optimal Treatment of Patients P.78 | | | SY22 How far can we go? Palliative and end-of-life care at home P.230 | LOE 15:00-16:30 | | ES26 Strategies of Cancer genomics for H&N Cancers P.100 | |
| | Meet the Experts① Conference Room 436 | 3F Bldg.4 | | ME9 Are current follow up strategies for head and neck cancer still fit for purpose? P.231 | E 8:50-9:50 | ME10 What is the next cutting-edge treatment for urothelial carcinoma? P.231 | | | | | | 15:00-17:00 | | | |
| | Meet the Experts② Conference Room 437 | 3F Bldg.4 | | ME11 Essence of an Investigator, my message to young doctors in gynecologic oncology P.232 | E 8:50-9:50 | ME12 Dermatological approach to patients with cancer- the value of a multidisciplinary approach P.232 | | | | | | | | | |
| | PAP Room Exhibition Room 212 | 1F Bldg.2 | PAP2 PAP Orientation② 8:00-8:15 | | | PAP2 PAP Special Lecture② 9:35-10:20 | PAP2 PAP Special Lecture③ 10:30-11:15 | PAP2 PAP Basic Lecture⑥ 11:25-12:10 | PAP2 Promoting Shared Decision Making by patient 12:20-13:05 | | | PAP2 PAP Basic Lecture⑦ 16:15-17:00 | PAP2 PAP Special Lecture④ 17:10-17:55 | | |
| | Poster Room | | | 8:00-9:00 | Putting Up Posters | 9:00-11:30 | 11:30-12:15 | 12:15-13:30 | Poster Removal & Putting Up Posters | | | 13:30-17:10 | 17:10-17:55 | 17:55-19:00 | Poster Session |
| | | | | | | | | | | | | | | | |

① Cafeteria Cascade B1F, Bldg.3
 ② Shirotori Hall 1F, Bldg.4
 ③ Conference Room 438 3F, Bldg.4
 ④ Aisle 3F, Bldg.3
 ⑤ Lounge 3F, Bldg.2

Time Table
Day 3, Saturday, February 24

| | | | | | | |
|----|--|---------------------------------|------------------------|------------------------|--------------------------------|-----------------|
| 凡例 | PS = Presidential Session | SJS = SIOG/JSMO Joint Symposium | CP = Committee Program | ES = Evening Seminar | HoD = Highlight of the Day | L = ライブ配信 |
| | AJS = ASCO/JSMO Joint Symposium | JS = Joint Symposium | ME = Meet The Experts | O = Oral Session | PAP = Patient Advocate Program | O = オンデマンド配信 |
| | APJS = Asia-Pacific/JSMO Joint Symposium | PSY = Presidential Symposium | MeS = Medical Seminar | MO = Mini Oral Session | | 同時通訳 (英⇄日) |
| | EJS = ESMO/JSMO Joint Symposium | SY = Symposium | MoS = Morning Seminar | P = Poster Session | | English Session |

| | | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
|--|--|-----------|--|---|---|---|--|--|---|---|--|---|----|----|--|
| Nagoya International Conference Center | Room 1 Century Hall | 2F Bldg.1 | | PSY6 L O 8:20-9:50 Considering the use of Real World Data for clinical development and daily clinical practice P.271 | PS4 L O E 9:50-11:50 Gastrointestinal Cancer, Hepatobiliary/ Pancreatic Cancer P.271 | | MeS27 L 12:00-12:50 Up-to-date treatment strategy for DLBCL P.79 | | PSY7 L O 13:45-15:15 Should cancer treatment be centralized or equalized? P.272 | HoD3 L O 15:15-16:45 Highlight of the Day 3 P.273 | | | | | |
| | Room 2 Reception Hall | 4F Bldg.1 | MoS13 7:20-8:10 Concept of perioperative drug therapy for HR-positive HER2-negative breast cancer P.87 | SY23 L O E 8:20-9:50 Perioperative systemic treatment in early-stage non-small cell lung cancer P.274 | PSY8 L O n 9:50-11:50 New drug loss in new drug development P.274 | | MeS28 L n 12:00-12:50 BRCA1/2 related breast cancer: Insights into adjuvant therapy strategies P.79 | | SY24 L O E 13:55-15:15 Perioperative chemotherapy for gastric cancer: Role of ICI? P.275 | O15 15:15-16:45 Multidisciplinary Team Program P.276 | | | | | |
| | Room 3 Conference Rooms 141+142 | 4F Bldg.1 | MoS14 7:20-8:10 Appearance Care and Issues facing Patients with Cancer P.87 | SY25 L O E 8:20-9:50 Novel Therapy Development and Strategies in HR-Positive Breast Cancer - Looking 5 Years into the Future P.277 | | SY26 L O E 10:05-11:35 Current and future of liquid biopsy P.277 | | MeS29 L n 12:00-12:50 Immunotherapy in Biliary Tract Cancer P.79 | | JS7 L O 13:55-15:35 New Treatment progress for Bone Metastases What's Next role, beside Palliation, Quality of Life Improvement? P.278 | MO36 E 15:45-16:45 Head and Neck Cancer 1 (head and neck cancer 1, thyroid cancer, salivary gland cancer, systemic therapy) P.279 | | | | |
| | Room 4 International Conference Room | 3F Bldg.3 | MoS15 7:20-8:10 A treatment strategy aimed at maximizing the therapeutic effects of lenvatinib derived from 13 years of experience in use P.87 | SJS L O n 8:20-9:50 Sustainable Cancer Care for Older Adults P.280 | | CP6 L O E 10:20-11:50 Women's Oncologists Union Workshop P.280 | | MeS30 L n 12:00-12:50 Skin disorder management with immune checkpoint inhibitors P.79 | | SY27 L O E 13:55-15:25 Pathology in collaboration with AI P.281 | | MO37 16:05-16:45 Clinical Trial Facilitation Program 1 P.281 | | | |
| | Room 5 Conference Rooms 431+432 | 3F Bldg.4 | MoS16 L 7:20-8:10 Treatment Strategy for EGFR Wildtype Lung Cancer - Focusing on Potential of Histone Demethylase Inhibitor P.88 | MO38 E 8:20-9:20 Gastrointestinal Cancer 6 (Others) P.283 | MO39 E 9:20-10:20 Gastrointestinal Cancer 7 (Colorectal Cancer, Biomarker) P.283 | MO40 E 10:20-11:20 Gastrointestinal Cancer 8 (Colorectal Cancer, Anti-EGFR antibody) P.284 | | MeS31 E 12:00-12:50 Evolving benefits of immune checkpoint inhibitors in advanced gastric cancer P.80 | | MO41 E 13:55-14:55 Rare Cancer 4 (Pediatric - Sarcoma 1) P.285 | MO42 E 14:55-15:55 Gastrointestinal Cancer 9 (Colorectal Cancer, Angogenesis Inhibitor) P.286 | | | | |
| | Room 6 Conference Rooms 131+132 | 3F Bldg.1 | MoS17 L O 7:20-8:10 The diagnosis of bone metastasis in CT follow-up exam supported by the temporal subtraction P.88 | MO43 E 8:20-9:20 Genitourinary Cancer 2 (Genitourinary Cancer) P.287 | MO44 E 9:25-10:25 Genitourinary Cancer 3 (Development of biomarkers of genitourinary cancer) P.287 | | MeS32 12:00-12:50 New approach of supportive care for changes of the cancer treatment environment: Chemotherapy-induced alopecia and scalp cooling P.80 | | MO45 13:55-14:55 Multidisciplinary Team Program 3 P.288 | | MO46 E 15:30-16:30 Hematologic Malignancies 4 (Other (Myeloma etc.)) P.289 | | | | |
| | Room 7 Conference Rooms 133+134 | 3F Bldg.1 | MoS18 L 7:20-8:10 Reactivation of Hepatitis B Virus Caused by Chemotherapy and Immunosuppressive Therapy - Prevention of Acute Liver Failure P.89 | MO47 E 8:20-9:20 Rare Cancer 5 (Cancer of unknown primary, Other) P.291 | MO48 E 9:20-10:20 Rare Cancer 6 (Sarcoma 2) P.291 | MO49 10:20-11:20 Patient Advocacy 2 P.292 | | MeS33 12:00-12:50 The Pursuit of Personalized Medicine Unraveling from Evidence and Experience P.80 | | MO50 E 13:55-15:05 Hepatobiliary/ Pancreatic Cancer 4 (Gallbladder and Biliary Tract Cancer 2) P.293 | MO51 E 15:20-16:30 Hepatobiliary/ Pancreatic Cancer 5 (Liver Cancer) P.294 | | | | |
| | Room 8 Conference Room 234 | 3F Bldg.2 | MoS19 7:20-8:10 Optimization of the lung cancer genetic testing: Insight from an Advanced Medicine A trial using MMS P.89 | Advanced Seminar for CRC 8:20-10:50 | | | | MeS34 E 12:00-12:50 Checkmate 816: A turning point for a new era of care for patients with resectable NSCLC P.80 | | MO52 E 13:55-14:55 Gynecologic Cancer 2 P.295 | MO53 E 15:30-16:30 Translational Research/ Clinical Pharmacology 3 (TR in Breast Cancer) P.295 | | | | |
| | Room 9 Conference Rooms 232+233 | 3F Bldg.2 | MoS20 L 7:20-8:10 Treatment strategies for unresectable pancreatic cancer based on the latest clinical trial results P.89 | O16 E 8:20-9:50 Hematologic Malignancies P.297 | MO54 E 9:50-10:50 Head and Neck Cancer 2 (head and neck cancer 2, systemic therapy) P.297 | MO55 E 10:50-11:50 Head and Neck Cancer 3 (head and neck cancer 3, local therapy) P.298 | | MeS35 L E 12:00-12:50 Optimal treatment of patients with metastatic breast cancer: incorporating the multidisciplinary team and shared decision making P.81 | | MO56 13:55-14:55 Cross-sectional Program 3 (Translational research/ Medical education) P.299 | MO57 E 15:30-16:30 Gastrointestinal Cancer 10 (Esophageal Cancer, Metastatic, CRT) P.300 | | | | |
| | Room 10 Conference Room 224 | 2F Bldg.2 | MoS21 L O E 7:20-8:10 Antibody-Drug Conjugates: Shifting Paradigm in Cancer Therapy P.90 | SY28 L O n 8:20-9:50 Current Status and Issues of Career Support for Pediatric and AYA Cancer Patients and Survivors P.302 | SY29 L O n 9:50-11:20 Dermatologic adverse events and appearance care - Global trends and issues - P.303 | | MeS36 E 12:00-12:50 New results from clinical trials in breast cancer P.81 | | MO58 E 13:55-14:55 Lung Cancer/ Thoracic Cancer 6 (Small Cell Lung Cancer - Other Thymic Malignancies) P.303 | O17 E 15:00-16:30 Lung Cancer/ Thoracic Cancer 3 P.304 | | | | | |
| | Room 11 Conference Room 221 | 2F Bldg.2 | MoS22 7:20-8:10 Tips for Multiplex Testing in Lung Cancer - To detect KRAS G12C mutation-positive lung cancer - P.90 | MO59 8:20-9:00 Clinical Trial Facilitation Program 2 P.305 | CP7 9:45-11:15 Board-certified Oncologists Association Program P.305 | | MeS37 L 12:00-12:50 Chemotherapy for Colorectal Cancer: Best Practices from the Latest Topics P.81 | | Medical Oncology Seminar 14:00-17:00 | | | | | | |
| | Room 12 Conference Rooms 222+223 | 2F Bldg.2 | MoS23 7:20-8:10 A Personalized Treatment for Multiple Myeloma Patients to Realize Well-being P.91 | MO60 E 8:20-9:20 Translational Research/ Clinical Pharmacology 4 (ccDNA and Phase I) P.307 | | MO61 E 10:20-11:20 Hematologic Malignancies 5 (Lymphoma 3) P.307 | | MeS38 L 12:00-12:50 Expectations for anti-CTLA-4 antibody "Imjudo" in lung and liver cancer P.82 | | MO62 E 13:55-14:55 Breast Cancer 5 (Perioperative chemotherapy) P.308 | MO63 E 15:00-16:00 Breast Cancer 6 (Biomarker) P.309 | | | | |
| | Room 13 Exhibition Room 211 | 1F Bldg.2 | MoS24 7:20-8:10 Strategic Changes and Positioning of Anti-EGFR Antibodies in Colorectal Cancer Chemotherapy P.91 | SY30 L O E 8:20-9:50 Advances in Systemic Therapy in Biliary Tract Cancer P.310 | O18 E 9:50-11:20 Breast Cancer P.310 | | MeS39 L 12:00-12:50 Biomarkers of gastric cancer P.82 | | CP8 L O 13:55-15:25 Go far, go together! ~ Multidisciplinary care and Careers for Tomorrow: Proposals from JSMO 2024 ~ P.311 | MO64 15:40-16:30 Palliative Care/ Symptom Management 3 P.312 | | | | | |
| | Meet the Experts① Conference Room 436 | 3F Bldg.4 | | | ME14 E 8:40-9:40 Immunotherapy for gastroesophageal cancer: a 2024 update P.313 | ME15 E 10:20-11:20 Antibody-drug conjugate and Novel therapy in Lung Cancer P.313 | | | | | | | | | |
| | Meet the Experts② Conference Room 437 | 3F Bldg.4 | | | ME16 8:40-9:40 Tumor agnostic HER2-targeted drug development P.314 | ME17 E 10:20-11:20 Systemic therapy for Biliary tract cancer P.314 | | | | | | | | | |
| | PAP Room Exhibition Room 212 | 1F Bldg.2 | PAP3 8:00-8:15 PAP Orientation③ | PAP3 L O 8:30-9:20 PAP Applied Lecture① | PAP3 L O 9:30-10:20 PAP Applied Lecture② | PAP3 L O 10:30-11:20 PAP Applied Lecture③ | | PAP3 L 12:00-12:50 Patient Empowerment の実践 | | PAP3 14:00-16:10 PAP Applied Lecture④ | | | | | |
| | Poster Room | | | 8:00-9:00 Putting Up Posters | | Poster Display | | 9:00-13:00 Poster Session | 13:00-13:45 Poster Removal | | | | | | |
| | | | | | | | | | | | | | | | |

① Cafeteria Cascade B1F, Bldg.3
 ② Shirotori Hall 1F, Bldg.4
 ③ Conference Room 438 3F, Bldg.4
 ④ Aisle 3F, Bldg.3
 ⑤ Lounge 3F, Bldg.2